NeueHealth, a technology company specializing in value-based care connections between providers and payers, has announced a significant shift in its corporate structure through a $1.3 billion acquisition deal. The company will transition to private ownership under an affiliate of New Enterprise Associates (NEA) and a group of investors, marking a new chapter in its development.
The merger agreement offers current common stockholders $7.33 per share in cash, representing a substantial 70% premium over the company's December 23 closing price. In a strategic move, several existing stakeholders, including NEA and 12 current NeueHealth investors, have opted for rollover agreements. These arrangements allow them to exchange their current holdings for equity interests in the newly formed private entity.
"We are pleased to announce this transaction as we believe it places NeueHealth in a strong position for continued growth while maximizing value for all of NeueHealth's public stockholders," stated Mike Mikan, president and CEO of NeueHealth. "NEA has been a longstanding strategic partner, and we look forward to continuing to work together to build on NeueHealth's success as a leader in value-based care."
The transition maintains stability in key areas, with the current executive leadership team remaining in place and committing to convert their entire equity interests into the new private structure. The company's existing secured loan facility with Hercules Capital will also continue unchanged.
This acquisition follows several strategic moves by NeueHealth throughout 2024, including the complete acquisition of Centrum Health, one of its value-driven clinic brands, by purchasing the remaining 25% equity stake. The company also secured a $150 million loan facility from Hercules Capital to support its strategic initiatives. Earlier in the year, the organization, formerly known as Bright Health Group, rebranded to NeueHealth and began trading under the NYSE ticker symbol NEUE.
The completion of the merger remains subject to stockholder approval and standard regulatory clearances. This transaction represents a significant development in the healthcare technology sector, potentially influencing the landscape of value-based care delivery.
Click here for the original news story